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Background: Mycoplasma hominis is a fastidious micro-organism causing systemic infections in the neonate and
genital infections in the adult. It can also be the cause of serious extra-genital infections, mainly in
immunosuppressed or predisposed subjects.
Case Presentation: We describe a case of severe pneumonia and pericarditis due to Mycoplasma hominis in a
previously healthy adolescent who did not respond to initial therapy.
Conclusions: Mycoplasma hominis could be an underestimated cause of severe pneumonia in immunocompetent
patients and should be particularly suspected in those not responding to standard therapy.
Background
Mycoplasma hominis (M. hominis) belongs to the order
of Mycoplasmatales, prokaryotes that lack a cell wall.
This characteristic has implications for antibiotic ther-
apy as many commonly used antibiotics act by inhibiting
the bacterial cell wall synthesis. Mycoplasma organisms
have fastidious growth requirements and are often diffi-
cult to culture on a cell-free medium. A recent analysis
of the M. hominis genome sequence revealed that it is
the second smallest genome among self-replicating free
living organisms with a predicted genome of 537 coding
genes [1]. M. hominis is an opportunistic organism that
is uncommonly associated with infection in humans.
However, it is frequently isolated from the urogenital
and respiratory tract of asymptomatic healthy persons
[2]. Infants may be colonized following vaginal delivery
but M. hominis is rarely recovered from prepubertal
children. Colonization in postpubertal individuals results
mainly from sexual contact [3].
M. hominis exceptionally penetrates the submucosal
layer, unless the patient is immunosupressed or trauma-
tized (through accident or instrumentation). In this case,
it can invade the bloodstream and disseminate to many
different organs and tissues throughout the body, caus-
ing extragenital infections [4]. However, extragenital
infections are uncommon in healthy patients and cases
of pneumonia are exceptional.
M. hominis is an organism recognized to be intrinsi-
cally resistant to macrolides. In addition, there is recent
evidence of increasing resistance to tetracycline and
emerging resistance to fluoroquinolones [5-7].
Case Presentation
A previously healthy 15-year-old sexually active female
came to the emergency room because of dyspnoea, fever
and right thoracic pain. The physical examination was
suggestive of right sided pneumonia and laboratory tests
revealed a marked leukocytosis (39’800/mm
3 WBC, 89%
neutrophils; 74% segmented and 15% bands) and an ele-
vated C-reactive protein level (>250 mg/L). The chest
X-ray confirmed the clinical suspicion of right lobar
pneumonia and an outpatient treatment of oral clari-
thromycin (500 mg bid) was started. The absence of
clinical improvement and the onset of a pleural effusion
on the fourth day of antibiotic therapy lead to admission
to our hospital and the addition of i.v. ceftriaxone (2 g
bid) to the macrolide regimen.
As the high fever persisted, a chest CT scan was done
on the seventh day of antibiotic treatment, showing a
bilateral necrotizing pneumonia as well as a bilateral
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sumed polymicrobial infection including anaerobes, a
treatment of i.v. amoxicillin/clavulanate (2.2 g tid) was
substituted to the previous clarithromycin-ceftriaxone
regimen.
Two days later the patient was transferred to the paedia-
tric intensive care unit because of rapid worsening of her
symptoms with the risk of respiratory failure. Amoxicillin/
clavulanate therapy was switched to imipenem-cilastatin
(500 mg i.v. qid) and vancomycin (750 mg i.v. tid).
Cultures of pleural effusion for aerobic and anaerobic
pathogens obtained by needle aspiration were negative. M.
hominis was then detected by eubacterial PCR [DNA
extracts were amplified using PCR targeting the 16S rRNA
as follows: forward primer (Bak11wF): 5’-AGTTT-
GATCMTGGCTCAG-3’, reverse Primer (Pc3 mod): 5’-
GGACTACHAGGGTATCTAAT-3’,s e q u e n c i n gp r i m e r :
Bak11wf and Bak533 r: 5’-TTACCGCGGCTGCTGGCAC-
] [3], and confirmed by a M. hominis specific Taqman PCR
(98,500,000 copies/mL). The primers of the TaqMan PCR
used were: Forward primer: 5’-TTTGGTC
AAGTCCTGCAACGA-3’, Reverse Primer: 5’-CCCCAC
CTTCCTCCCAGTTA-3’ and probe: FAM-TTACTAA-
CATTAAGTTGAGGACTCTA-MGB, targeting the M.
hominis 16 rRNA gene sequence [8], and further confirmed
by specific culture (Mycoplasma IST, bioMérieux, France).
The antibiotic susceptibility tests revealed resistance to
macrolides and susceptibility to tetracyclines and quino-
lones, leading to the addition of doxycycline (100 mg
bid) twelve days after the start of symptoms.
A new CT scan showed a larger amount of pleural
fluid as well as a pericardial effusion (Figure 1).
Because of worsening respiratory and haemodynamic
conditions, the pericardial and pleural effusions were
evacuated by pericadiectomy with window and pleural
drainage by chest tube insertion. Any respiratory sup-
port (other than oxygen supplementation) was needed
thereafter. M. hominis DNA was also amplified in the
pericardial fluid by specific PCR (85 copies/mL). Stan-
dard axenic cultures and specific PCR assays for Strepto-
coccus pneumoniae and Staphylococcus aureus,a sw e l l
as Legionella pneumophila urinary antigen test were
negative in all specimens. Complement-fixing antibody
to Mycoplasma pneumoniae showed no increase in
titers.
Imipenem-cilastin and vancomycine were discontinued
while doxycycline was administered for a total of
2 weeks. This treatment was associated with clinical and
biological improvement and the patient could be dis-
charged from the hospital on day 19. At this time, the
CRP level was down to 16 mg/L. Finally the patient
completely recovered without any sequel on the chest
X-ray.
Discussion
We described a case of severe pneumonia and pericardi-
tis due to M. hominis in a previously healthy adolescent
who completely recovered under doxycycline therapy.
M. hominis was detected from the pleural and pericar-
dial fluids by eubacterial PCR assay and subsequent
Figure 1 CT scan of the thorax showing bilateral necrotizing pneumonia (black circles) and pleural effusion (black squares) as well as
pericardial effusion (leftwards arrows). Note the presence of a chest tube inserted into the pleural cavity (in communication with the lung
abscess) and a drainage tube into the pericardial cavity (downwards arrows).
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has been identified by culture, molecular or serological
diagnostic procedures.
M. hominis may cause genital infections in adults and
may be involved in neonatal infections. Serious extra-
genital infections, such as brain abscess, pneumonia,
mediastinitis, pericarditis, endocarditis, osteitis and
arthritis, wound infections, peritonitis, and pyelonephri-
tis have been reported, mainly in immunosuppressed
patients [9-12]. However, such cases have also been
described in immunocompetent patients, particularly in
individuals with predisposing factors such as trauma,
altered cardiorespiratory function and complicated uro-
genital manipulations or surgery.
Our review of the literature identified 11 cases of
M. hominis pneumonia in immunocompetent patients
(Additional file 1) [13-17].
Six cases occurred in patients with pre-existing
co-morbidities (trauma or surgery, subarachnoid hae-
morrhage, and oesophageal carcinoma), one case in a
pregnant woman, and four cases in patients with no
known predisposing conditions.
Complete resolution has been described in the five
patients who received antibiotic therapy active against
M. hominis. In contrast, among those receiving an
inadequate antibiotic therapy, four died and two recov-
ered suggesting that untreated M. hominis infection may
aggravates pre-existing conditions and lead to death.
Initially, our patient experienced a severe worsening of
her clinical condition while on antibiotics active against
common respiratory pathogens, but has fully recovered
after receiving an antimicrobial drug active against M.
hominis.
M. hominis may be an underestimated cause of severe
pneumonia in previously healthy patients, particularly
when other common etiological agents have been ruled
out in those not responding to standard therapy.
The M. hominis strain isolated in our patient was sus-
ceptible to both tetracyclines and quinolones. We used
a susceptibility assay based on breakpoint cut offs set
according to the recommendations of the Clinical and
Laboratory Standards Institute (CLSI) [18].
Unpublished data from our center on the antibiotic
susceptibility of M. hominis strains isolated from the
genital and respiratory tracts between 2000 and 2008
are in accordance with the data from the literature: 55%
are susceptible to ciprofloxacin (5/9), 100% are suscepti-
ble to doxycycline (11/11), and 100% are resistant to
clarithromycin (9/9).
M. hominis is intrinsically resistant to macrolides
[19-21], and tetracyclines have been considered the
drugs of choice. However, the therapeutic activity of tet-
racyclines may become unreliable due to resistance phe-
nomena induced by previous antibiotic exposure.
Moreover, they are no longer a valid therapeutic option
in some areas [5,7]. As no resistance to levofloxacin (or
other newer fluoroquinolones) and clindamycin is yet
identified, these drugs could be a suitable therapeutic
alternative [5,7,20,22,23]. The increasing resistance of
M. hominis strains to antibiotics makes guidance of
therapy by in vitro susceptibility tests of paramount
importance in invasive infections leading to life-
threatening situations.
Conclusions
This case report shows the role of M. hominis as a pos-
sible etiologic agent in a previous healthy adolescent
suffering a severe and complicated pneumonia not
responding to macrolide and b-lactam agents.
The eubacterial PCR is a useful tool to detect unusual
pathogens.
The efficacy of traditional drugs such as tetracyclines
on M. hominis is affected by increasing resistance, mak-
ing susceptibility testing an important issue nowadays.
The newest fluoroquinolones are an attractive option to
treat invasive infections caused by M. hominis.
Consent
Written informed consent was obtained from the patient
and her mother for publication of this case report. A
copy of the written consent is available for review by
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Additional material
Additional file 1: Table S1: Summary of previously reported
Mycoplasma hominis pneumonia in immunocompetent patients.
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